Procter & Gamble Health Ltd (PGHL)
₹5,670.50
Mkt cap
₹9,395 Cr
P/E ratio
28.20
P/B
17.94
Div yield
2.74%
ROE
61.90%
ROCE
83.90%
EPS (TTM)
₹201.08
Book value
₹316
52W range
4,779–6,919
Sector
Healthcare
Price history
Previous close
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. [1]
NSE PGHLBSE 500126
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsNeutral
52-week range
−18.04% from high₹5,671
₹4,779+18.66% from low₹6,919
Current
₹5,670.50
Prev close
₹5,651.00
Day
+0.35%
Price performance
1D
+0.35%
1W
−1.69%
1M
−7.71%
3M
−8.72%
6M
+16.70%
1Y
−10.15%
YTD
−0.54%
Financials
Revenue, profit & margin
P/E ratio
28.2×
PGHL is 17% below the sector median of 34.0×
PGHL28.2×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 | |
| Expenses | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 | |
| Operating Profit | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 | |
| OPM % | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% | |
| Other Income | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | |
| Profit before tax | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 | |
| Tax % | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% | |
| Net Profit | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 | |
| EPS in Rs | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.26% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | +1.26% |
| +1 day | −1.68% |
| +5 days | −2.24% |
| +15 days | −6.55% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202651.82%Promoter
Promoters51.82%
FIIs6.33%0.13
DIIs12.44%1.23
Public29.41%1.11
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| PGHL | ₹5,660.00 | 28.20 | 9,395 | 2.74% | 96 | +9.50% | 364 | +7.37% | 83.88% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2013nse
Concall transcripts7
Credit ratings5
Announcements5
Re-Appointment Of Mr. S. Madhavan As Independent Director Of The Company. 4 Sep - Shareholders approved Mr. S. Madhavan’s five-year reappointment as Independent Director from November 15, 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 4 SepShareholder Meeting / Postal Ballot-Outcome of AGM 3 Sep59Th Annual General Meeting Of The Company 12 Aug - Annual Report 2025-26 and AGM notice; 59th AGM on September 3, 2026.Business Responsibility and Sustainability Reporting (BRSR) 12 Aug - Filed Business Responsibility & Sustainability Report for FY ended March 31, 2026.